Table 9.

Female Pubertal Assays: Frequency of Endpoint Alterations

	Study data: statistically altered endpoint (0 = not altered; 1 = altered))
Endpoint	Aa	B	C	D	E	F	G	H	Ie	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	Statistically altered endpoint (%)
Body wtb/gain (prepuberty)c	0	1	0	0	1	0	1	0	1	0	0	0	0	1	1	0	1	0	0	0	0	0	0	30
Body wt/gain (termination)	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	13
Absolute age at vaginal opening (VO)	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	17
Adjusted age at VO	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	17
Absolute body wt at VO	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	9
Adjusted body weight at VO	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	9
Age at first estrus	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
Estrous cycle length	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
Percent cycling	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
Percent regularly cycling	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
Relative liver wt	1	1	0	1	1	1	1	1	1	0	0	0	0	1	1	0	0	0	1	0	0	0	1	52
Relative kidney wt	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	0	0	0	0	0	0	0	1	26
Relative pituitary wt	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	17
Relative adrenal wt	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
Absolute ovarian wt	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	13
Adjusted ovarian wt	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	17
Absolute uterine wet wt	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	13
Adjusted uterine wet wt	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	13
Absolute uterine blotted wt	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	9
Adjusted uterine blotted wt	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	17
Absolute thyroid wt	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
Adjusted thyroid wt	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
Blood urea nitrogen (BUN)	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	13
Creatinine	1	0	0	1	1f	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	17
Serum T4 levels	0	1	0	0	1	0	1	NA	NA	0	0	1	0	0	0	0	1	0	0	0	0	0	0	24
Serum TSH levels	0	1	0	0	1	0	1	NA	NA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14
Thyroid follicular cell height	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	13
Thyroid colloid amount	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13
Thyroid histopathologyd	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	13
Ovarian histopathology	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
Uterine histopathology	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
Kidney histopathology	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	9

^aData in this table reflect the same studies referenced in Table 1, although the sequence has been changed.

^bwt, Weight.

^cBody weight/body weight gain during intervals leading up to vaginal opening (e.g., PND 28–33).

1 = Statistically significant difference in treated group(s) compared with concurrent controls; 0 = no difference between treated and control groups.

^dHistopathology results for thyroid, ovary, uterus, and kidneys were qualitative; therefore, 1 = treatment-related difference and 0 = no difference from controls.

^eAntiestrogenic

^fNo corresponding kidney histopathology or consistent changes with BUN. NA = not applicable